`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`CLARKSBURG DIVISION
`
`
`
`
`Case No. 1:22-cv-00061-TSK
`
`JURY TRIAL DEMANDED
`
`
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`
`
`
`Plaintiff,
`
`
`v.
`
`
`
`Defendant.
`
`
`
`
`
`
`
`REGENERON’S STIPULATION REGARDING
`SUMMARY JUDGMENT AND CASE NARROWING
`
`On April 20, 2023, Mylan moved for summary judgment of certain claims in U.S. Patent
`
`Nos. 10,888,601, 11,084,865, 11,253,572 and 11,104,715 (ECF 429).
`
`
`
`Subject to all appellate rights, including but not limited to rights of appeal concerning
`
`claim construction, Regeneron does not oppose summary judgment as to the following claims,
`
`under the Court’s Claim Construction (ECF 427), on the following bases:
`
` Regeneron accepts summary judgment of noninfringement of claims 2-3, 6, 12-14,
`
`and 16 of U.S. Patent No. 11,104,715.
`
` Regeneron accepts summary judgment of invalidity of claims 5-6 and 9 of U.S.
`
`Patent No. 10,888,601.
`
` Regeneron accepts summary judgment of invalidity of claims 1-5, 8-11, 14, and 26-
`
`28 of U.S. Patent No. 11,253,572.
`
`Regeneron opposes summary judgment with respect to all other bases and all other
`
`claims that are the subject of Mylan’s motion, and will file an opposition to Mylan’s motion
`
`accordingly.
`
`1
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2031 Page 1
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 433 Filed 04/27/23 Page 2 of 4 PageID #: 29443
`
`
`
`Pursuant to the Court’s Scheduling Order (ECF 87), Regeneron hereby narrows these
`
`initial proceedings to the following patents and claims:
`
`1. U.S. Patent No. 10,888,601: Claims 11, 19, and 27
`
`2. U.S. Patent No. 11,084,865: Claims 4, 7, 9, 11, and 14-18
`
`3. U.S. Patent No. 11,253,572: Claims 6, 7, 12, 13, 18, 19, 22, 23, and 25
`
`
`
` CAREY DOUGLAS KESSLER & RUBY, PLLC
`
`/s/ Steven R. Ruby
`Steven R. Ruby (WVSB No. 10752)
`David R. Pogue (WVSB No. 10806)
`707 Virginia Street East
`901 Chase Tower (25301)
`P.O. Box 913
`Charleston, West Virginia 25323
`(304) 345-1234
`sruby@cdkrlaw.com
`drpogue@cdkrlaw.com
`
`
`
`
`
`Date: April 26, 2023
`
`
`Of Counsel:
`
`David I. Berl (admitted PHV)
`Ellen E. Oberwetter (admitted PHV)
`Thomas S. Fletcher (admitted PHV)
`Andrew V. Trask (admitted PHV)
`Teagan J. Gregory (admitted PHV)
`Shaun P. Mahaffy (admitted PHV)
`Sean M. Douglass (admitted PHV)
`Kathryn S. Kayali (admitted PHV)
`Arthur J. Argall III (admitted PHV)
`Adam Pan (admitted PHV)
`Nicholas Jordan (admitted PHV)
`Haylee N. Bernal Anderson (admitted PHV)
`Renee M. Griffin (admitted PHV)
`Rebecca Carter (admitted PHV)
`
`WILLIAMS & CONNOLLY LLP
`680 Maine Avenue, SW
`Washington, DC 20024
`(202) 434-5000
`dberl@wc.com
`eoberwetter@wc.com
`tfletcher@wc.com
`atrask@wc.com
`tgregory@wc.com
`smahaffy@wc.com
`sdouglass@wc.com
`kkayali@wc.com
`aargall@wc.com
`
`2
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2031 Page 2
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 433 Filed 04/27/23 Page 3 of 4 PageID #: 29444
`
`apan@wc.com
`njordan@wc.com
`handerson@wc.com
`rgriffin@wc.com
`rebeccacarter@wc.com
`
`Andrew E. Goldsmith (admitted PHV)
`Evan T. Leo (admitted PHV)
`Jacob E. Hartman (admitted PHV)
`Mary Charlotte Y. Carroll (admitted PHV)
`Sven E. Henningson (admitted PHV)
`
`KELLOG, HANSEN, TODD, FIGEL &
`FREDERICK, P.L.L.C.
`1615 M Street, N.W., Suite 400
`Washington, D.C. 20036
`TEL: (202) 326-7900
`agoldsmith@kellogghansen.com
`eleo@kellogghansen.com
`jhartman@kellogghansen.com
`Mcarroll@kellogghansen.com
`shenningson@ kellogghansen.com
`
`Counsel for Plaintiff Regeneron Pharmaceuticals, Inc.
`
`3
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2031 Page 3
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 433 Filed 04/27/23 Page 4 of 4 PageID #: 29445
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on April 26, 2023, the foregoing was served on Mylan’s counsel of
`
`record via email because the filing function of the Court’s CM/ECF system was unavailable. I
`
`further certify that on April 27, 2023, after the issue with the CM/ECF system was resolved, the
`
`foregoing was electronically filed with the Clerk of the Court via the Court’s CM/ECF system,
`
`which will serve counsel of record for all parties.
`
`
`
`/s/ Steven R. Ruby
`Steven R. Ruby (WVSB No. 10752)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2031 Page 4
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`